Inhibition of Src but not Syk causes weak reversal of GPVI-mediated platelet aggregation measured by light transmission aggregometry
Platelets. 2022 May 9:1-8. doi: 10.1080/09537104.2022.2069235. Online ahead of print.ABSTRACTSrc tyrosine kinases and spleen tyrosine kinase (Syk) have recently been shown to contribute to sustained platelet aggregation on collagen under arterial shear. In the present study, we have investigated whether Src and Syk are required for aggregation under minimal shear following activation of glycoprotein VI (GPVI) and have extended this to C-type lectin-like receptor-2 (CLEC-2) which signals through the same pathway. Aggregation was induced by the GPVI ligand collagen-related peptide (CRP) and the CLEC-2 ligand rhodocytin and m...
Source: Platelets - May 10, 2022 Category: Hematology Authors: Hilaire Yam Fung Cheung Luis A Moran Albert Sickmann Johan W M Heemskerk Ángel Garcia Steve P Watson Source Type: research
Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient
Perm J. 2021 Dec 14;25. doi: 10.7812/TPP/21.125.ABSTRACTThis case report describes a successful outcome involving a patient with severe COVID-19 viral pneumonia utilizing a novel therapeutic approach with the glycoprotein IIb/IIIa inhibitor, eptifibatide.PMID:35348110 | DOI:10.7812/TPP/21.125 (Source: The Permanente journal)
Source: The Permanente journal - March 29, 2022 Category: General Medicine Authors: Patrick Joseph Merrill R Mark Bradburne Source Type: research
Successful Use of Glycoprotein IIb/IIIa Inhibitor Involving Severely Ill COVID-19 Patient
Perm J. 2021 Dec 14;25:21.125. doi: 10.7812/TPP/21.125.ABSTRACTThis case report describes a successful outcome involving a patient with severe COVID-19 viral pneumonia utilizing a novel therapeutic approach with the glycoprotein IIb/IIIa inhibitor, eptifibatide.PMID:35348110 | PMC:PMC8784086 | DOI:10.7812/TPP/21.125 (Source: The Permanente journal)
Source: The Permanente journal - March 29, 2022 Category: General Medicine Authors: Patrick Joseph Merrill R Mark Bradburne Source Type: research
Eptifibatide bridging therapy for staged carotid artery stenting and cardiac surgery: Safety and feasibility
CONCLUSIONS: For patients undergoing staged CAS-CTS, Eptifibatide bridging therapy is a viable temporary antiplatelet strategy with a favorable safety profile. This strategy enables a flexible range of time-intervals between procedures.PMID:35341420 | DOI:10.1177/17085381221084813 (Source: Vascular)
Source: Vascular - March 28, 2022 Category: Surgery Authors: M Travis Caton Kazim H Narsinh Amanda Baker Matthew R Amans Steven W Hetts Joseph H Rapp James C Ianuzzi Elaine Tseng Warren J Gasper Daniel L Cooke Source Type: research
